10x Genomics Surpasses Earnings Expectations with Strong Q4 Revenue

10x Genomics, a leader in genomic analysis tools, reported a fourth-quarter earnings performance that exceeded analysts’ expectations. The company announced a GAAP earnings per share (EPS) of – $0.13, surpassing predictions by $0.08. Revenue for the quarter reached $166 million, marking a slight increase of 0.6% year-over-year and exceeding estimates by $5.65 million.

The results, released in a press statement from 10x Genomics, signal a positive trajectory for the company as it navigates the competitive landscape of genomic research and diagnostics. The solid revenue performance is indicative of strong demand for the company’s innovative products and services, which have been crucial for researchers in various fields.

Looking ahead, 10x Genomics projects full-year revenue for 2026 to fall between $600 million and $625 million. This forecast is slightly below the consensus estimate of $611.77 million. The company’s guidance reflects its continued commitment to expanding its market presence while adapting to evolving industry demands.

In providing context, the company emphasized its focus on enhancing its product offerings and investing in research and development. This strategy aims to not only retain existing customers but also attract new clientele as genomic technologies continue to advance.

The financial results and projections are expected to resonate positively with investors, affirming 10x Genomics‘s position in the market. As the demand for genomic insights grows, the company is poised to capitalize on opportunities within the sector. With a robust pipeline and an innovative approach, 10x Genomics remains a key player in driving forward the future of genomics.